Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: A need for tolerance induction therapy

Journal of the American Society of Nephrology

Volumn 25, Issue 4, 2014, Pages 675-680

  Debiec, Hanna ^a,b   Valayannopoulos, Vassili ^c   Boyer, Olivia ^d   Nöel, Laure Hélène ^c   Callard, Patrice ^e   Sarda, Hélène ^e   De Lonlay, Pascale ^c   Niaudet, Patrick ^d   Ronco, Pierre ^a,f  

^a Urgences Néphrologiques et Transplantation Rénale Hôpital Tenon 4   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSERM US24 CNRS UMS3633   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f CENTRE HOSPITALIER RENÉ DUBOS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENZYME ANTIBODY; GALSULFASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G4; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; ALLOANTIBODY; ARYLSULFATASE B, HUMAN; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

ALLOIMMUNITY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CASE REPORT; CHILD; CONGENITAL NEPHROTIC SYNDROME; DRUG INFUSION; DRUG PULSE THERAPY; DRUG TOLERANCE; ELECTRON MICROSCOPY; ENZYME REPLACEMENT; HEMATURIA; HIP DYSPLASIA; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LOW DRUG DOSE; MALE; MAROTEAUX LAMY SYNDROME; MEMBRANOUS GLOMERULONEPHRITIS; ORTHOPEDIC SURGERY; PERIPHERAL EDEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; REBOUND; STEROID THERAPY; VASCULAR LESION; BIOSYNTHESIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MALE; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; RECOMBINANT PROTEINS;

EID: 84901454107     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013030290     Document Type: Article

References (24)

1. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G, Ronco PM: Antenatal membranous glomeru-lonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346: 2053-2060, 2002
2. Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T, de Heer E, Soubrier F, Janssen F, Ronco P: Role of truncating mutations in MME gene in fetomaternal alloim-munisation and antenatal glomerulopathies. Lancet 364: 1252-1259, 2004
3. Hudson BG: The molecular basis of Good-pasture and Alport syndromes: Beacons for the discovery of the collagen IV family. JAm Soc Nephrol 15: 2514-2527, 2004
4. Patrakka J, Ruotsalainen V, Reponen P, Qvist E, LaineJ, Holmberg C, Tryggvason K, Jalanko H: Recurrence of nephrotic syndrome in kidney grafts of patients with congenital ne-phrotic syndrome of the Finnish type: Role of nephrin. Transplantation 73: 394-103, 2002
5. Richards SM: Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin Appl Immunol Rev2: 241-253, 2002
6. Brooks DA: Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab 68: 268-275, 1999
7. Koren E, Zuckerman LA, Mire-Sluis AR: Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr Pharm Biotechnol 3: 349-360, 2002
8. Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, Chen YT, Richards SM, Phillips JA 3rd, Fogo AB, Tiller GE: Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 114: e532-e535, 2004
9. Winchester B, Vellodi A, Young E: The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 28: 150-154, 2000
10. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S: Mucopolysaccharidosis VI. Or-phanet J Rare Dis 5: 5, 2010
11. Dixon FJ, Feldman JD, Vazquez JJ: Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis. J Exp Med 113: 899-920, 1961
12. Glassock RJ: Human idiopathic membranous nephropathy-a mystery solved? N Engl J Med 361: 81-83, 2009
13. Ronco P, Debiec H: Pathogenesis of membranous nephropathy: Recent advances and future challenges. Nat Rev Nephrol 8: 203-213, 2012
14. Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11 -21, 2009
15. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T, Ronco P: Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 364: 2101-2110, 2011
16. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ; MPS VI Phase 3 Study Group: Enzyme replacementtherapyformucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. JPediatr 148: 533-539, 2006
17. Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, Steiner RD, Leão Teles E, Valayannopoulos V; CSP Study Group: Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 36:373-384, 2013
18. Giardino L, Armelloni S, Corbelli A, Mattinzoli D, Zennaro C, GuerrotD, Tourrel F, Ikehata M, Li M, Berra S, Carraro M, Messa P, Rastaldi MP: Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier. J Am Soc Nephrol 20: 1929-1940, 2009
19. Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K: Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, h IK1, by volatile anesthetics. Eur J Pharmacol 395: 95-101, 2000
20. Morton MJ, Hutchinson K, Mathieson PW, Witherden IR, Saleem MA, Hunter M: Human podocytes possess a stretch-sensitive, Ca2 +-activated K+ channel: Potential implications for the control of glomerular filtration. JAmSocNephrol15: 2981-2987, 2004
21. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S, Davison M, Corzo D, Chen YT: Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149: 89-97, 2006
22. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93: 2081-2088, 1999
23. Wang J, Lozier J, Johnson G, Kirshner S, Verthelyi D, Pariser A, Shores E, Rosenberg A: Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment. Nat Biotechnol 26: 901-908, 2008
24. Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, Aucouturier P, Godin M, Ronco P: Recurrent membranous ne-phropathy in an allograft caused by IgG3k targeting the PLA2 receptor. J Am Soc Nephrol 23: 1949-1954, 2012